The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.

By Robert J. Johnston Jr., Laetitia Comps-Agrar, J. Hackney, Xin Yu, M. Huseni, Yagai Yang, Summer Park, Vincent Javinal, H. Chiu, B. Irving and 2 more. Cancer Cell, 2014

1,090 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/42cbf896bb5d46978638d2f5bc44cabc4af4b191

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Lieping Chen
2. J. Wolchok
3. D. Pardoll
4. W. Zou
5. E. Wherry
6. Kristen E. Pauken
7. Ton N. Schumacher
8. J. Snyder-Cappione

In Oncology

1. Lieping Chen
2. J. Wolchok
3. D. Pardoll
4. W. Zou
5. Ton N. Schumacher
6. E. Wherry
7. Kristen E. Pauken
8. D. Thommen

Citations in the corpus

• PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations (2016, background): “Thus, the combinations of PD pathway with Tim-3, LAG3, and TIGIT blockade have been proposed and tested in clinical trials (NCT01968109 and NCT02460224).”
• Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. (2019, neutral): “…to inhibit effector CD8+ T cell function. flow cytometry, and suppression assay mammalian cell lines, mouse model, human tumor and PBMC samples Johnston et al. (2014) Kurtulus et al. (2015) IDO1 0.013039684 38 3 out of 8 indoleamine 2,3- dioxygenase 1 other immune inhibitors IDO1 is the…”
• MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. (2016, background): “Combinations of anti-PD-L1with blocking antibodies to other negative regulators such as TIGIT (Johnston et al., 2014) might broaden responses, but the ability to combine with targeted agents—those that attack oncogenic driver pathways as well as those that attack T cell exhaustive pathways— will be ”
• OMIP‐037: 16‐color panel to measure inhibitory receptor signatures from multiple human immune cell subsets (2017, background): “TIGIT is expressed on exhausted T cells in both cancer and chronic viral infections and anti-TIGIT antibody blockade can enhance T cell effector functions (29).”